Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14885MR)

This product GTTS-WQ14885MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14885MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7343MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ8948MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14882MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ2174MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ10513MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ11337MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ8352MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ11869MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW